ACLARION INC (ACON) Stock Price, Quote, News and Overview
NASDAQ:ACON - Nasdaq - US6551872012 - Common Stock
ACON Quote and Key Statistics
ACLARION INC
NASDAQ:ACON (1/21/2025, 8:00:00 PM)
Premarket: 0.0446 +0 (+4.94%)0.0425
+0 (+0.47%)
ACON Financial Highlights
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -191.03% | ||
| ROE | -359.3% | ||
| Debt/Equity | 0.47 |
ACON Performance and Technical Analysis
ACON Ownership and Analysts
ACON Latest News and Analysis
Get insights into the top gainers and losers of Tuesday's after-hours session.
Get insights into the top gainers and losers of Tuesday's after-hours session.
The trading volume of these stocks is deviating from the norm in today's session.
Join us as we delve into today's session and uncover the stocks that are standing out with unusual volume.
Which stocks are most active on Thursday?
Discover the most active stocks in Thursday's session. Stay informed about the stocks that are generating the most trading volume!
Discover the most active stocks in Wednesday's session. Stay informed about the stocks that are generating the most trading volume!
Curious about the most active stocks on Wednesday? Find out which stocks are dominating the market action!
Aclarion Announces Closing of $14.4 Million Public Offering of Common Stock and Warrants
BROOMFIELD, CO - January 17, 2025 (NEWMEDIAWIRE) - Aclarion, Inc. (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW), a healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence (AI) algorithms to help physicians identify the location of chronic low back pain, today announced the closing of an underwritten public offering of 100,000 shares of common stock and 143,900,000 pre-funded warrants with each share of common stock and each pre-funded warrant accompanied by (i) a series A common warrant to purchase one (1) common share at an exercise price of $0.20 per share and (ii) a series B common warrant to purchase one (1) common share at an exercise price of $0.20 per share. The combined public offering price of each share of common stock together with the accompanying series A and series B common warrants is $0.10, and the combined public offering price of each pre-funded warrant together with the accompanying series A and series B common warrants is $0.09999. In addition, the Company granted to the underwriter a 45 day option to purchase up to an additional 21,000,000 shares of its common stock (or pre-funded warrants), at the public offering price, less underwriting discounts and commissions, and up to an additional 21,000,000 series A common warrants and up to an additional 21,000,000 series B common warrants at a nominal price to cover over-allotment sales. The underwriter exercised its option to purchase 21,000,000 series A common warrants and 21,000,000 series B common warrants. All shares of common stock, pre-funded warrants, series A common warrants and series B common warrant were sold by Aclarion. The closing of the public offering occurred on January 16, 2025.
Aclarion Announces Closing of $14.4 Million Public Offering of Common Stock and Warrants
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
About ACON
Company Profile
Aclarion, Inc. is a healthcare technology company, which engages in the provision of Magnetic Resonance Spectroscopy (MRS), and a proprietary biomarker to optimize clinical treatments. The company is headquartered in Broomfield, Colorado and currently employs 6 full-time employees. The company went IPO on 2022-04-22. The firm leverages magnetic resonance spectroscopy (MRS), and proprietary biomarkers to optimize clinical treatments. The company has developed a software application called NOCISCAN. The product uses the existing MRS capabilities of many commercially available scanners to non-invasively analyze the chemical makeup of intervertebral discs in the spine. The software post-processes the MRS exam data and detects the presence of chemical biomarkers that the Company has demonstrated to be associated with degenerative pain and structural integrity of the lumbar discs. The company uses a magnet to apply a pulsed magnetic field to a patient, sensors to detect radio waves that emanate from the resonant vibrations of different chemicals in the body in response to that pulsed magnetic field and a computer to create detailed images of tissue structures in the patient based on those detected chemical signals.
Company Info
ACLARION INC
8181 Arista Place, Ste 100
Broomfield COLORADO US
Employees: 5
Company Website: https://aclarion.com/
Investor Relations: https://investors.aclarion.com/
Phone: 18332752266
ACON Competitors/Peers
Symbol | Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| VEEV | VEEVA SYSTEMS INC-CLASS A | 35.69 | 36.21B | ||
| DOCS | DOXIMITY INC-CLASS A | 49.57 | 10.37B | ||
| WAY | WAYSTAR HOLDING CORP | N/A | 6.55B | ||
| CERT | CERTARA INC | 32.33 | 2.03B | ||
| GDRX | GOODRX HOLDINGS INC-CLASS A | 14.72 | 1.80B | ||
| TDOC | TELADOC HEALTH INC | N/A | 1.64B | ||
| PHR | PHREESIA INC | N/A | 1.59B | ||
| SDGR | SCHRODINGER INC | N/A | 1.55B | ||
| EVH | EVOLENT HEALTH INC - A | 11.18 | 1.19B | ||
| HSTM | HEALTHSTREAM INC | 49.06 | 969.77M | ||
| LFMDP | LIFEMD INC - LFMD 8 7/8 PERP | N/A | 945.39M | ||
| DH | DEFINITIVE HEALTHCARE CORP | 12.97 | 683.46M |